The global label-free array systems market size was valued at USD 455.91 million in 2022 and is expected to expand at a compound annual growth rate (CAGR) of 7.42% from 2023 to 2030. The increasing demand for personalized medicine, as well as a variety of other factors such as the prevalence of chronic diseases, increased research activities in biomedical science, the need for high-throughput screening, and the demand for cost-effective and efficient systems. In June 2022, a scientific report published by Springer Nature Limited stated the development of a label-free multiplex electrochemical immunosensor for detecting the characteristics of Pompe, Gaucher and Krabbe disease. The research concluded that immunosensor showcased good sensitivity and is applicable in POC testing settings for the early diagnosis of lysosomal storage disorders. Hence, increasing applications are likely to have a positive impact on the demand for a label-free array.
Additionally, government funding for research activities and the emergence of new technologies such as nanotechnology are also contributing to market growth. Companies such as Bruker are at the forefront of these developments. For instance, in June 2018 the company launched new systems such as the Sierra SPR-32 system, which is equipped with R3 software that provides high sensitivity and the highest SPR throughput. This software increases the instrument's precision and productivity, and the label-free strategies will help accelerate the process of taking chemical entities to clinical trials.
Moreover, the COVID-19 pandemic challenged the existing diagnostics tools and compelled companies to develop the product in the line of infection detection. For instance, in January 2023, professionals from various institutions conducted collaborative research to develop an interdigitated microelectrode array-based impedimetric immunosensor to identify and monitor COVID-19 antibodies. The immunosensor is a label-free technology and is suitable for point-of-care applications. The COVID-19 pandemic encouraged companies and researchers to develop a cost-efficient and accurately label-free array-based diagnostic tool to detect the infection.
Along with that, a number of companies have entered the market for label-free array systems. For instance, in November 2018, Agilent Technologies acquired ACEA Biosciences, a company that develops and manufactures label-free array systems for the detection and analysis of biomolecules. This acquisition was likely made in order to expand Agilent's portfolio of products and services in the label-free array systems market. This highlights the growing demand for label-free detection methods in the field of biological and biomedical research.
Surface plasmon resonance held the major share of the label-free array system market in 2022 with 34.96%. The largest market share is attributed to high R&D investments by prominent market players. In addition, the increasing risk of lifestyle-related chronic diseases is anticipated to drive clinical urgency to incorporate these systems, thus propelling the label-free array system market over the forecast period. For instance, Sartorius offers a range of solutions to meet the global demand for vaccine research, antibody fragment characterization, and whole-cell biologics.
Along with that, bio-layer interferometry is widely employed in numerous applications. However, the primary application is considered to be drug discovery and development. It is a highly preferable technique, since it is fully automated, fast, and requires minimal intervention by the users. It is also an optimal approach for measuring the interactions between macromolecular through assessing the interference patterns.
The drug discovery segment showcased a significant growth rate during the forecasted period with 34.96% of the market share in 2022. The label-free analytical approach allows real-time and high-resolution monitoring of kinetic interaction. Accurate data on kinetics is important in drug development since it assists in identifying and isolating therapeutic molecules for their target. This can shorten the timespan to discover, and streamline the selection of ideal candidates for drugs with optimal chances of success downstream.
Protein interface analysis is expected to capture a considerable market share in 2022. Owing to the limitations of labeling strategies, the development of reliable, sensitive, and label-free arrays is drawing substantial attention. For instance, Proteon XPR36 by Bio-Rad is a protein interaction array system based on SPR technology to identify and monitor interactions of biomolecular for assessing label-free interactions.
Pharmaceutical and biotechnology companies segment is expected to have the largest proportion of the market share in 2022 with 44.76%. The major firms are also investing in R&D to provide products and services for the early detection and management of chronic diseases. As a result, organizations are embracing improved analytical technologies, propelling the worldwide label-free array system market. The assessment of biomolecular interactions through label-free array systems along with the study of drug interactions holds great importance in the pharmaceutical segment.
The academic & research institutes segment is expected to witness considerable growth with a CAGR of 7.19%. The increasing grant programs by companies and regulatory bodies to encourage the use of the label-free analytical technique is anticipated to a be significant growth factor for the market. The key sponsors for the research and development in the market include regional governments, venture capitalists, and companies.
North America accounted for the largest share of the market in 2022 with 47.20%, owing to the presence of major companies, extensive government funding, and an increase in research activities in the region. In addition, the use of antibody characterization in research programs by universities in the U.S. and Canada. These have accelerated the progress in the biotechnology sector, thereby increasing the demand for high-throughput analytical technology solutions in laboratory workflows. North America is expected to maintain its market dominance over the forecast period owing to the rapid adoption of advanced technological solutions, high investments in R&D, and rising wages of skilled personnel in this region.
The markets within Asia Pacific are projected to grow at the fastest rate during the forecast period, which can be attributed to the increasing interest of key global players in capturing regional revenue share by expanding into emerging markets. Global investors are increasingly investing in China and India due to economic developments. Similarly, regional players are strengthening their presence in the global label-free array system market.
Label-free array systems have become increasingly popular and are used by a wide range of companies, from small startups to large multinational corporations. companies are engaged in the development, manufacturing, and marketing of label-free array systems and their accessories to meet the requirements of various industries. For instance, ForteBio is a leading provider of label-free array systems, such as the Octet Red system, which is a label-free, real-time biosensor used to study protein-protein interactions, protein-ligand interactions, and protein stability. The system is widely used in pharmaceutical and biotechnology research to aid in the discovery and development of new drugs and is marketed and sold by Pall ForteBio in the United States. Some of the key players in the global label-free array system market include:
Thermo Fisher Scientific Inc.
Agilent Technologies Inc.
Bio-Rad Laboratories Inc.
F. Hoffmann-La Roche AG
Becton Dickinson and Company
Market size value in 2023
USD 484.63 million
Revenue forecast in 2030
USD 799.59 million
CAGR of 7.42% from 2023 to 2030
Base year for estimation
2018 - 2021
2023 - 2030
Revenue in USD million and CAGR from 2023 to 2030
Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Type, application, end-user, region
North America; Europe; Asia Pacific; Latin America; MEA
U.S.; Canada; Germany; UK; France; Italy; Spain; Denmark; Sweden; Norway; China; Japan; India; South Korea; Australia; Thailand; Brazil; Mexico, Argentina; South Africa; Saudi Arabia, UAE; Kuwait
Key companies profiled
Illumina; Inc.; Thermo Fisher Scientific; Inc.; Agilent Technologies; Inc.; PerkinElmer; Inc.; Merck KGaA; Danaher Corporation; Bio-Rad Laboratories; Inc.; F. Hoffmann-La Roche AG; Becton; Dickinson and Company; Sartorius AG.
Free report customization (equivalent up to 8 analyst’s working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options
Avail customized purchase options to meet your exact research needs. Explore purchase options
This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2018 to 2030. For this report, Grand View Research has segmented the label-free array system market report based on type, application, end-user, and region.
Type Scope Outlook (Revenue, USD Million, 2018 - 2030)
Surface Plasmon Resonance
Cellular Dielectric Spectroscopy
Application Scope Outlook (Revenue, USD Million, 2018 - 2030)
Protein Interface Analysis
End-user Scope Outlook (Revenue, USD Million, 2018 - 2030)
Pharmaceutical & Biotechnology Companies
Academic & Research Institutes
Regional Scope Outlook (Revenue, USD Million, 2018 - 2030)
Middle East & Africa
b. The global label-free array system market size was estimated at USD 455.91 million in 2022 and is expected to reach USD 484.63 million in 2023.
b. The global label-free array system market is expected to grow at a compound annual growth rate of 7.4% from 2023 to 2030 to reach USD 799.59 million by 2030.
b. North America dominated the label-free array systems market with a share of 47.2% in 2022. This is attributable to presence of major companies, extensive government funding, and an increase in research activities in the region.
b. Some key players operating in the label-free array system market include Illumina, Inc., Thermo Fisher Scientific, Inc., Agilent Technologies, Inc., PerkinElmer, Inc., Merck KGaA, Danaher Corporation, Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche AG, Becton, Dickinson and Company, and Sartorius AG
b. Key factors that are driving the market growth include increasing demand for personalized medicine, as well as a variety of other factors such as the prevalence of chronic diseases, increased research activities in biomedical science, the need for high-throughput screening, and the demand for cost-effective and efficient systems.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities. Contact us now
"The quality of research they have done for us has been excellent."